Stem Cell-Derived Exosomes as Nanotherapeutics for Inflammatory Diseases

Abstract

Inflammation, as a complex biological response, can lead to tissue damage and pathological physiological changes, forming the basis for many chronic diseases. Stem cell-derived exosomes (SC-Exos), a type of nanoscale extracellular vesicle, possess advantages such as small volume, low immunogenicity, and drug-carrying capacity, demonstrating immense potential in the field of disease diagnostics and therapeutics. Current studies indicate that SC-Exos can not only alleviate inflammatory diseases by suppressing inflammatory cytokines and modulating the activation of macrophages through their immunomodulatory and regenerative properties but also show significant potential as carriers for anti-inflammatory drugs, presenting a promising therapeutic approach for inflammatory conditions. However, the current lack of systematic summaries of SC-Exos in the treatment of inflammatory diseases has impeded the development of standardized therapies and clinical applications. This review elucidates the methods of SC-Exo sourcing, isolation, characterization, and engineering, as well as their application, mechanisms of action, and efficacy in the treatment of inflammatory diseases such as periodontitis, osteoarthritis (OA), and inflammatory bowel disease. Integrating these findings, this review highlights that SC-Exos can attenuate a variety of inflammatory diseases by transporting a diverse range of molecules to modulate immune responses, thereby providing foundations for subsequent standardization of production and clinical trials.

Keywords

diseases / exosomes / inflammation / nanotechnology / stem cells

References

[1] L. M.Coussens and Z.Werb, “Inflammation and Cancer,” Nature 420, no. 6917 (2002):860–867.

[2] S. I.Grivennikov, F. R. Greten, and M.Karin, “Immunity, Inflammation, and Cancer,” Cell 140, no. 6 (2010):883–899.

[3] S.Keshtkar, N.Azarpira, and M. H.Ghahremani, “Mesenchymal Stem Cell-Derived Extracellular Vesicles: Novel Frontiers in Regenerative Medicine,” Stem Cell Research & Therapy 9, no. 1 (2018):63.

[4] M.Madrigal, K. S.Rao, and N. H.Riordan, “A Review of Therapeutic Effects of Mesenchymal Stem Cell Secretions and Induction of Secretory Modification by Different Culture Methods,” Journal of Translational Medicine 12 (2014):260.

[5] L.Hidalgo-Garcia, J. Galvez, M. ERodriguez-Cabezas, and P. O.Anderson, “Can a Conversation Between Mesenchymal Stromal Cells and Macrophages Solve the Crisis in the Inflamed Intestine?,” Frontiers in Pharmacology 9 (2018):179.

[6] B.Crivelli, T.Chlapanidas, S.Perteghella, et al., “Mesenchymal Stem/Stromal Cell Extracellular Vesicles: From Active Principle to Next Generation Drug Delivery System,” Journal of Controlled Release 262 (2017):104–117.

[7] M.Hao, M.Duan, Z.Yang, et al., “Engineered Stem Cell Exosomes for Oral and Maxillofacial Wound Healing,” Frontiers in Bioengineering and Biotechnology 10 (2022):1038261.

[8] E. R.Brannon, M. V.Guevara, N. J.Pacifici, J. K.Lee, J. S.Lewis, and O.Eniola-Adefeso, “Polymeric Particle-Based Therapies for Acute Inflammatory Diseases,” Nature Reviews Materials 7, no. 10 (2022):796–813.

[9] Z.Tu, Y.Zhong, H.Hu, et al., “Design of Therapeutic Biomaterials to Control Inflammation,” Nature Reviews Materials 7, no. 7 (2022):557–574.

[10] C.Gelli, M.Tarocchi, L.Abenavoli, L.Di Renzo, A.Galli, and A.De Lorenzo, “Effect of a Counseling-Supported Treatment With the Mediterranean Diet and Physical Activity on the Severity of the Non-Alcoholic Fatty Liver Disease,” World Journal of Gastroenterology 23, no. 17 (2017):3150–3162.

[11] M. C.Mentella, F.Scaldaferri, C.Ricci, A.Gasbarrini, and G. A. D. Miggiano, “Cancer and Mediterranean Diet: A Review,” Nutrients 11, no. 9 (2019):2059.

[12] S.Acosta, A.Johansson, and I.Drake, “Diet and Lifestyle Factors and Risk of Atherosclerotic Cardiovascular Disease—A Prospective Cohort Study,” Nutrients 13, no. 11 (2021):3822.

[13] Y.-B.Zhang, X.-F.Pan, J.Chen, et al., “Combined Lifestyle Factors, All-Cause Mortality and Cardiovascular Disease: A Systematic Review and Meta-Analysis of Prospective Cohort Studies,” Journal of Epidemiology and Community Health 75, no. 1 (2021):92–99.

[14] S.Zappavigna, A. M.Cossu, A.Grimaldi, et al., “Anti-Inflammatory Drugs as Anticancer Agents,” International Journal of Molecular Sciences 21, no. 7 (2020):2605.

[15] C.Zhou, “Mutual Repression Between Steroid and Xenobiotic Receptor and NF-κB Signaling Pathways Links Xenobiotic Metabolism and Inflammation,” Journal of Clinical Investigation 116, no. 8 (2006):2280–2289.

[16] T.Uchida, N.Iwamoto, S.Fukui, et al., “Comparison of Risks of Cancer, Infection, and MACEs Associated With JAK Inhibitor and TNF Inhibitor Treatment: A Multicentre Cohort Study,” Rheumatology 62, no. 10 (2023):3358–3365.

[17] M.Arabpour, A.Saghazadeh, and N.Rezaei, “Anti-Inflammatory and M2 Macrophage Polarization-Promoting Effect of Mesenchymal Stem Cell-Derived Exosomes,” International Immunopharmacology 97 (2021):107823.

[18] B.Zhang, R. W. Y. Yeo, R. C.Lai, E. W. K.Sim, K. C.Chin, and S. K.Lim, “Mesenchymal Stromal Cell Exosome–Enhanced Regulatory T-Cell Production Through an Antigen-Presenting Cell–Mediated Pathway,” Cytotherapy 20, no. 5 (2018):687–696.

[19] J.Wang, J.Xia, R.Huang, et al., “Mesenchymal Stem Cell-Derived Extracellular Vesicles Alter Disease Outcomes via Endorsement of Macrophage Polarization,” Stem Cell Research & Therapy 11 (2020):424,

[20] W.Liu, M.Yu, D.Xie, et al., “Melatonin-Stimulated MSC-Derived Exosomes Improve Diabetic Wound Healing Through Regulating Macrophage M1 and M2 Polarization by Targeting the PTEN/AKT Pathway,” Stem Cell Research & Therapy 11, no. 1 (2020):424.

[21] Y.Hu, Z.Wang, C.Fan, et al., “Human Gingival Mesenchymal Stem Cell-Derived Exosomes Cross-Regulate the Wnt/β-catenin and NF-κB Signalling Pathways in the Periodontal Inflammation Microenvironment,” Journal of Clinical Periodontology 50, no. 6 (2023):796–806.

[22] S.Toldo, E.Mezzaroma, L. F.Buckley, et al., “Targeting the NLRP3 Inflammasome in Cardiovascular Diseases,” Pharmacology & Therapeutics 236 (2021):108053.

[23] J.Fu and H.Wu, “Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation,” Annual Review of Immunology 41 (2023):301–316.

[24] Y.Liu, D. T.Graves, and S.Wang, “Development and Clinical Application of Human Mesenchymal Stem Cell Drugs,” Science Bulletin 68, no. 9 (2023):860–863.

[25] J.Li, K.Liu, Y.Liu, et al., “Exosomes Mediate the Cell-to-Cell Transmission of IFN-α-induced Antiviral Activity,” Nature Immunology 14, no. 8 (2013):793–803.

[26] M. D.Hade, C. N.Suire, and Z.Suo, “Mesenchymal Stem Cell-Derived Exosomes: Applications in Regenerative Medicine,” Cells 10, no. 8 (2021):1959.

[27] H.Bao, M.Wu, J.Xing, et al., “Enzyme-Like Nanoparticle–Engineered Mesenchymal Stem Cell Secreting HGF Promotes Visualized Therapy for Idiopathic Pulmonary Fibrosis In Vivo,” Science Advances 10, no. 34 (2024): eadq0703.

[28] L.-L.Yu, J.Zhu, J.-X.Liu, et al., “A Comparison of Traditional and Novel Methods for the Separation of Exosomes From Human Samples,” BioMed Research International 2018 (2018):1–9.

[29] Y.Zhang, J.Bi, J.Huang, Y. Tang, S.Du, and P.Li, “Exosome: A Review of Its Classification, Isolation Techniques, Storage, Diagnostic and Targeted Therapy Applications,” International Journal of Nanomedicine 15 (2020):6917–6934.

[30] Y.Wang, S.Wang, L.Li, Y.Zou, B.Liu, and X. Fang, “Microfluidics-Based Molecular Profiling of Tumor-Derived Exosomes for Liquid Biopsy,” VIEW 4, no. 2 (2023):20220048.

[31] X.Li, W.Wang, J.Chen, et al., “The Potential Role of Exosomal Mirnas and Membrane Proteins in Acute HIV-Infected People,” Frontiers in Immunology 13 (2022):939504.

[32] Y.Jiang, F.Wang, K.Wang, et al., “Engineered Exosomes: A Promising Drug Delivery Strategy for Brain Diseases,” Current Medicinal Chemistry 29, no. 17 (2022):3111–3124.

[33] W.Zhang, Z.Wan, D.Qu, et al., “Profibrogenic Macrophage-Targeted Delivery of Mitochondrial Protector via Exosome Formula for Alleviating Pulmonary Fibrosis,” Bioactive Materials 32 (2024):488–501.

[34] X.Ma, B.Liu, L.Fan, et al., “Native and Engineered Exosomes for Inflammatory Disease,” Nano Research 16, no. 5 (2023):6991–7006.

[35] C.Xu, C.Jiang, Z.Li, et al., “Exosome Nanovesicles: Biomarkers and New Strategies for Treatment of Human Diseases,” MedComm 5, no. 8 (2024): e660.

[36] Z.Shen, S.Kuang, Y.Zhang, et al., “Chitosan Hydrogel Incorporated With Dental Pulp Stem Cell-Derived Exosomes Alleviates Periodontitis in Mice via a Macrophage-Dependent Mechanism,” Bioactive Materials 5, no. 4 (2020):1113–1126.

[37] X.Liu, X.Li, W.Zhu, et al., “Exosomes From Mesenchymal Stem Cells Overexpressing MIF Enhance Myocardial Repair,” Journal of Cellular Physiology 235, no. 11 (2020):8010–8022.

[38] D.Gala, S.Mohak, and Z.Fábián, “Extracellular Vehicles of Oxygen-Depleted Mesenchymal Stromal Cells: Route to Off-Shelf Cellular Therapeutics?,” Cells 10, no. 9 (2021):2199.

[39] R.Domenis, A.Cifù, S.Quaglia, et al., “Pro Inflammatory Stimuli Enhance the Immunosuppressive Functions of Adipose Mesenchymal Stem Cells-Derived Exosomes,” Scientific Reports 8 (2018):13325.

[40] B.Claridge, J.Lozano, Q. H.Poh, and D. W.Greening, “Development of Extracellular Vesicle Therapeutics: Challenges, Considerations, and Opportunities,” Frontiers in Cell and Developmental Biology 9 (2021):734720.

[41] X.Zhuang, X.Xiang, W.Grizzle, et al., “Treatment of Brain Inflammatory Diseases by Delivering Exosome Encapsulated Anti-Inflammatory Drugs From the Nasal Region to the Brain,” Molecular Therapy 19, no. 10 (2011):1769–1779.

[42] S.Ohno, M.Takanashi, K.Sudo, et al., “Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor Microrna to Breast Cancer Cells,” Molecular Therapy 21, no. 1 (2013):185–191.

[43] J.Wang, D.Chen, and E. A.Ho, “Challenges in the Development and Establishment of Exosome-Based Drug Delivery Systems,” Journal of Controlled Release 329 (2021):894–906.

[44] Y.Ma, S.Dong, X.Li, B. Y. S. Kim, Z.Yang, and W.Jiang, “Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy,” Frontiers in Oncology 10 (2021):606906.

[45] Z.Wang, J.Rich, N.Hao, et al., “Acoustofluidics for Simultaneous Nanoparticle-Based Drug Loading and Exosome Encapsulation,” Microsystems & Nanoengineering 8 (2022):45.

[46] D.Z, L.Q, D.X, et al., “Synergistic Therapy of a Naturally Inspired Glycopolymer-Based Biomimetic Nanomedicine Harnessing Tumor Genomic Instability,” Advanced Materials 33, no. 45 (2021): e2104594.

[47] T.Tian, H.-X.Zhang, C.-P.He, et al., “Surface Functionalized Exosomes as Targeted Drug Delivery Vehicles for Cerebral Ischemia Therapy,” Biomaterials 150 (2018):137–149.

[48] I.Gaurav, A.Thakur, A.Iyaswamy, X.Wang, X.Chen, and Z.Yang, “Factors Affecting Extracellular Vesicles Based Drug Delivery Systems,” Molecules 26, no. 6 (2021):1544.

[49] Q.Si, L.Wu, D.Pang, and P. Jiang, “Exosomes in Brain Diseases: Pathogenesis and Therapeutic Targets,” MedComm 4, no. 3 (2023): e287.

[50] J.Yang, Y.Li, S.Jiang, et al., “Engineered Brain-Targeting Exosome for Reprogramming Immunosuppressive Microenvironment of Glioblastoma,” Exploration (Early View): https://doi.org/10.1002/EXP.20240039.

[51] W.Lin, H.Yang, J.Lin, et al., “Oralexplorer: A Web Server for Exploring the Mechanisms of Oral Inflammatory Diseases,” Journal of Translational Medicine 22 (2024):282.

[52] W.Wen, Y.Pang, Y.Tian, et al., “Osteogenic Mesenchymal Stem Cells/Progenitors in the Periodontium,” Oral Diseases 30, no. 3 (2024):914–920.

[53] N. J.Kassebaum, A. G. C. Smith, E.Bernabé, et al., “Global, Regional, and National Prevalence, Incidence, and Disability-Adjusted Life Years for Oral Conditions for 195 Countries, 1990–2015: A Systematic Analysis for the Global Burden of Diseases, Injuries, and Risk Factors,” Journal of Dental Research 96, no. 4 (2017):380–387.

[54] B. G.Loos and T. E. Van Dyke, “The Role of Inflammation and Genetics in Periodontal Disease,” Periodontology 2000 83, no. 1 (2020):26–39.

[55] J.Sun, Z.Wang, P.Liu, et al., “Exosomes Derived From Human Gingival Mesenchymal Stem Cells Attenuate the Inflammatory Response in Periodontal Ligament Stem Cells,” Frontiers in Chemistry 10 (2022):863364.

[56] O.Trubiani, J.Pizzicannella, S.Caputi, et al., “Periodontal Ligament Stem Cells: Current Knowledge and Future Perspectives,” Stem Cells and Development 28, no. 15 (2019):995–1003.

[57] A.Tomokiyo, N.Wada, and H.Maeda, “Periodontal Ligament Stem Cells: Regenerative Potency in Periodontium,” Stem Cells and Development 28, no. 15 (2019):974–985.

[58] R.Wang, Q.Ji, C.Meng, et al., “Role of Gingival Mesenchymal Stem Cell Exosomes in Macrophage Polarization Under Inflammatory Conditions,” International Immunopharmacology 81 (2020):106030.

[59] Y.Zhao, Y.Shi, H.Yang, et al., “Stem Cell Microencapsulation Maintains Stemness in Inflammatory Microenvironment,” International Journal of Oral Science 14, no. 1 (2022):48.

[60] J. H.Park, K.Kim, J.Lee, et al., “A Cytoprotective and Degradable Metal–Polyphenol Nanoshell for Single-Cell Encapsulation,” Angewandte Chemie International Edition 53, no. 46 (2014):12420–12425.

[61] F.Lei, M.Li, T.Lin, H. Zhou, F.Wang, and X.Su, “Treatment of Inflammatory Bone Loss in Periodontitis by Stem Cell-Derived Exosomes,” Acta Biomaterialia 141 (2022):333–343.

[62] W.Liu, A.Konermann, T.Guo, A.Jäger, L.Zhang, and Y.Jin, “Canonical Wnt Signaling Differently Modulates Osteogenic Differentiation of Mesenchymal Stem Cells Derived From Bone Marrow and From Periodontal Ligament Under Inflammatory Conditions,” Biochimica et Biophysica Acta (BBA)—General Subjects 1840, no. 3 (2014):1125–1134.

[63] Y.Zheng, C.Dong, J.Yang, et al., “Exosomal microRNA-155-5p From PDLSCs Regulated Th17/treg Balance by Targeting Sirtuin-1 in Chronic Periodontitis,” Journal of Cellular Physiology 234, no. 11 (2019):20662–20674.

[64] K.Zhang, X.Zhao, X.Chen, et al., “Enhanced Therapeutic Effects of Mesenchymal Stem Cell-Derived Exosomes With an Injectable Hydrogel for Hindlimb Ischemia Treatment,” ACS Applied Materials & Interfaces 10, no. 36 (2018):30081–30091.

[65] P.Cs and K.Kl, “p38 MAPK Signaling in Oral-Related Diseases,” Journal of Dental Research 86, no. 9 (2007):812–825.

[66] S.Yu, X.Chen, Y.Liu, et al., “Exosomes Derived From Stem Cells From the Apical Papilla Alleviate Inflammation in Rat Pulpitis by Upregulating Regulatory T Cells,” International Endodontic Journal 55, no. 5 (2022):517–530.

[67] X.Kou, X.Xu, C.Chen, et al., “The fas/fap-1/cav-1 Complex Regulates IL-1RA Secretion in Mesenchymal Stem Cells to Accelerate Wound Healing,” Science Translational Medicine 10, no. 432 (2018): eaai8524.

[68] Z.Shen, J.Wang, Q.Huang, et al., “Genetic Modification to Induce CXCR2 Overexpression in Mesenchymal Stem Cells Enhances Treatment Benefits in Radiation-Induced Oral Mucositis,” Cell Death & Disease 9, no. 2 (2018):229.

[69] E.Mianehsaz, H. R.Mirzaei, M.Mahjoubin-Tehran, et al., “Mesenchymal Stem Cell-Derived Exosomes: A New Therapeutic Approach to Osteoarthritis?,” Stem Cell Research & Therapy 10 (2019):340.

[70] L.Pang, H.Jin, Z.Lu, et al., “Treatment With Mesenchymal Stem Cell-Derived Nanovesicle-Containing Gelatin Methacryloyl Hydrogels Alleviates Osteoarthritis by Modulating Chondrogenesis and Macrophage Polarization,” Advanced Healthcare Materials 12, no. 17 (2023): e2300315.

[71] S.Glyn-Jones, A. J. R. Palmer, R.Agricola, et al., “Osteoarthritis,” Lancet 386, no. 9991 (2015):376–387.

[72] Collaborators GdaIIaP. Global, Regional, and National Incidence, Prevalence, and Years Lived With Disability for 354 Diseases and Injuries for 195 Countries and Territories, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017,” Lancet 392, no. 10159 (2018):1789–1858.

[73] M. A.Ruiz Iban, J.Benavides, J. P.Forero, et al., “Use of Strong Opioids for Chronic Pain in Osteoarthritis: An Insight Into the Latin American Reality,” Expert Review of Clinical Pharmacology 11, no. 1 (2018):47–59.

[74] J.Lu, Y.Zhang, X.Yang, and H. Zhao, “Harnessing Exosomes as Cutting-Edge Drug Delivery Systems for Revolutionary Osteoarthritis Therapy,” Biomedicine & Pharmacotherapy 165 (2023):115135.

[75] H.Yu, Y.Huang, and L.Yang, “Research Progress in the Use of Mesenchymal Stem Cells and Their Derived Exosomes in the Treatment of Osteoarthritis,” Ageing Research Reviews 80 (2022):101684.

[76] J.Zeng, P.Sun, Y.Zhao, X. Fang, Z.Wu, and X.Qi, “Bone Mesenchymal Stem Cell-Derived Exosomes Involved Co-Delivery and Synergism Effect With Icariin via Mussel-Inspired Multifunctional Hydrogel for Cartilage Protection,” Asian Journal of Pharmaceutical Sciences 18, no. 3 (2023):100799.

[77] M. I.Guillén, M. Tofiño-Vian, A.Silvestre, M. A.Castejón, and M. J.Alcaraz, “Role of Peroxiredoxin 6 in the Chondroprotective Effects of Microvesicles From Human Adipose Tissue-Derived Mesenchymal Stem Cells,” Journal of Orthopaedic Translation 30 (2021):61–69.

[78] L.-H.Chang, S.-C.Wu, C.-H.Chen, et al., “Exosomes Derived From Hypoxia-Cultured Human Adipose Stem Cells Alleviate Articular Chondrocyte Inflammaging and Post-Traumatic Osteoarthritis Progression,” International Journal of Molecular Sciences 24, no. 17 (2023):13414.

[79] L. A.Vonk, S. F. J. van Dooremalen, N.Liv, et al., “Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Promote Human Cartilage Regeneration In Vitro,” Theranostics 8, no. 4 (2018):906–920.

[80] Y.Jin, M.Xu, H.Zhu, et al., “Therapeutic Effects of Bone Marrow Mesenchymal Stem Cells-Derived Exosomes on Osteoarthritis,” Journal of Cellular and Molecular Medicine 25, no. 19 (2021):9281–9294.

[81] S.-C.Tao, T.Yuan, Y.-L.Zhang, W. J. Yin, S. C.Guo, and C. Q.Zhang, “Exosomes Derived From miR-140-5p-overexpressing Human Synovial Mesenchymal Stem Cells Enhance Cartilage Tissue Regeneration and Prevent Osteoarthritis of the Knee in a Rat Model,” Theranostics 7, no. 1 (2017):180–195.

[82] Z.Wang, K.Yan, G.Ge, et al., “Exosomes Derived From miR-155-5p–overexpressing Synovial Mesenchymal Stem Cells Prevent Osteoarthritis via Enhancing Proliferation and Migration, Attenuating Apoptosis, and Modulating Extracellular Matrix Secretion in Chondrocytes,” Cell Biology and Toxicology 37, no. 1 (2021):85–96.

[83] X.Xu, Y.Liang, X.Li, et al., “Exosome-Mediated Delivery of Kartogenin for Chondrogenesis of Synovial Fluid-Derived Mesenchymal Stem Cells and Cartilage Regeneration,” Biomaterials 269 (2021):120539.

[84] H.Cao, M.Chen, X.Cui, et al., “Cell-Free Osteoarthritis Treatment With Sustained-Release of Chondrocyte-Targeting Exosomes From Umbilical Cord-Derived Mesenchymal Stem Cells to Rejuvenate Aging Chondrocytes,” ACS Nano 17, no. 14 (2023):13358–13376,

[85] S.Zhang, S. J.Chuah, R. C.Lai, J. H. P. Hui, S. K.Lim, and W. S.Toh, “MSC Exosomes Mediate Cartilage Repair by Enhancing Proliferation, Attenuating Apoptosis and Modulating Immune Reactivity,” Biomaterials 156 (2018):16–27.

[86] S.Zhang, K. Y. W. Teo, S. J.Chuah, R. C.Lai, S. K.Lim, and W. S.Toh, “MSC Exosomes Alleviate Temporomandibular Joint Osteoarthritis by Attenuating Inflammation and Restoring Matrix Homeostasis,” Biomaterials 200 (2019):35–47.

[87] S.Wang, B.Lei, E.Zhang, et al., “Targeted Therapy for Inflammatory Diseases With Mesenchymal Stem Cells and Their Derived Exosomes: From Basic to Clinics,” International Journal of Nanomedicine 17 (2022):1757–1781.

[88] Z.Zhao, L.Zhang, D. K. W.Ocansey, B.Wang, and F.Mao, “The Role of Mesenchymal Stem Cell-Derived Exosome in Epigenetic Modifications in Inflammatory Diseases,” Frontiers in immunology 14 (2023):1166536.

[89] L. P.Bruner, A. M.White, and S.Proksell, “Inflammatory Bowel Disease,” Primary Care: Clinics in Office Practice 50, no. 3 (2023):411–427.

[90] S. C.Ng, H. Y.Shi, N.Hamidi, et al., “Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies,” Lancet 390, no. 10114 (2017):2769–2778.

[91] Y.Yan, K.Li, J.Jiang, et al., “Perinatal Tissue-Derived Exosomes Ameliorate Colitis in Mice by Regulating the Foxp3 + Treg Cells and Gut Microbiota,” Stem Cell Research & Therapy 14 (2023):43.

[92] N.Heidari, H.Abbasi-Kenarsari, S.Namaki, et al., “Adipose-Derived Mesenchymal Stem Cell-Secreted Exosome Alleviates Dextran Sulfate Sodium-Induced Acute Colitis by Treg Cell Induction and Inflammatory Cytokine Reduction,” Journal of Cellular Physiology 236, no. 8 (2021):5906–5920.

[93] S.Yang, X.Liang, J.Song, et al., “A Novel Therapeutic Approach for Inflammatory Bowel Disease by Exosomes Derived From Human Umbilical Cord Mesenchymal Stem Cells to Repair Intestinal Barrier via TSG-6,” Stem Cell Research & Therapy 12 (2021):315.

[94] Y.Zhang, J.Chen, H.Fu, et al., “Exosomes Derived From 3D-Cultured MSCs Improve Therapeutic Effects in Periodontitis and Experimental Colitis and Restore the Th17 Cell/Treg Balance in Inflamed Periodontium,” International Journal of Oral Science 13 (2021):43.

[95] S. M.Man, “Inflammasomes in the Gastrointestinal Tract: Infection, Cancer and Gut Microbiota Homeostasis,” Nature Reviews Gastroenterology & Hepatology 15, no. 12 (2018):721–737.

[96] D.Wang, H.Xue, J.Tan, et al., “Bone Marrow Mesenchymal Stem Cells-Derived Exosomes Containing miR-539-5p Inhibit Pyroptosis Through NLRP3/Caspase-1 Signalling to Alleviate Inflammatory Bowel Disease,” Inflammation Research 71, no. 7–8 (2022):833–846.

[97] X.Cai, Z.-yZhang, J.-tYuan, et al., “hucMSC-Derived Exosomes Attenuate Colitis by Regulating Macrophage Pyroptosis via the miR-378a-5p/NLRP3 Axis,” Stem Cell Research & Therapy 12 (2021):416.

[98] Y.Xu, X.Tang, A.Fang, et al., “HucMSC-Ex Carrying miR-203a-3p.2 Ameliorates Colitis Through the Suppression of Caspase11/4-induced Macrophage Pyroptosis,” International Immunopharmacology 110 (2022):108925.

[99] H.Liu, Z.Liang, F.Wang, et al., “Exosomes From Mesenchymal Stromal Cells Reduce Murine Colonic Inflammation via a Macrophage-Dependent Mechanism,” JCI Insight 4, no. 24 (2019): e131273.

[100] Y.Kou, J.Li, Y.Zhu, et al., “Human Amniotic Epithelial Stem Cells Promote Colonic Recovery in Experimental Colitis via Exosomal MiR-23a–TNFR1–NF-κB Signaling,” Advanced Science 11, no. 44 (2024): e2401429.

[101] N.Li, L.Zhao, X.Geng, et al., “Stimulation by Exosomes From Hypoxia-Preconditioned Hair Follicle Mesenchymal Stem Cells Facilitates Mitophagy by Inhibiting the PI3K/AKT/mTOR Signaling Pathway to Alleviate Ulcerative Colitis,” Theranostics 14, no. 11 (2024):4278–4296.

[102] H.Gonzalez-King, N. A. García, I.Ontoria-Oviedo, M.Ciria, J. A.Montero, and P.Sepúlveda, “Hypoxia Inducible Factor-1α Potentiates Jagged 1-Mediated Angiogenesis by Mesenchymal Stem Cell-Derived Exosomes,” Stem Cells 35, no. 7 (2017):1747–1759.

[103] Z.Wei, S.Hang, D. K.Wiredu Ocansey, et al., “Human Umbilical Cord Mesenchymal Stem Cells Derived Exosome Shuttling miR-129-5p Attenuates Inflammatory Bowel Disease by Inhibiting Ferroptosis,” Journal of Nanobiotechnology 21 (2023):188.

[104] M.Guo, Z.Yin, F.Chen, and P. Lei, “Mesenchymal Stem Cell-Derived Exosome: A Promising Alternative in the Therapy of Alzheimer’s Disease,” Alzheimer’s Research & Therapy 12 (2020):109.

[105] M.Pajares, A. I.Rojo, G.Manda, L. Boscá, and A.Cuadrado, “Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications,” Cells 9, no. 7 (2020):1687.

[106] P.Xian, Y.Hei, R.Wang, et al., “Mesenchymal Stem Cell-Derived Exosomes as a Nanotherapeutic Agent for Amelioration of Inflammation-Induced Astrocyte Alterations in Mice,” Theranostics 9, no. 20 (2019):5956–5975.

[107] M. J.Haney, N. L.Klyachko, Y.Zhao, et al., “Exosomes as Drug Delivery Vehicles for Parkinson’s Disease Therapy,” Journal of Controlled Release 207 (2015):18–30.

[108] C. R.Harrell, A.Volarevic, V.Djonov, and V.Volarevic, “Mesenchymal Stem Cell-Derived Exosomes as New Remedy for the Treatment of Neurocognitive Disorders,” International Journal of Molecular Sciences 22, no. 3 (2021):1433.

[109] Y.-J.Kim, H.-J.Park, G.Lee, et al., “Neuroprotective Effects of Human Mesenchymal Stem Cells on Dopaminergic Neurons Through Anti-Inflammatory Action,” GLIA 57, no. 1 (2009):13–23.

[110] A.Schwerk, J.Altschüler, M.Roch, et al., “Adipose-Derived Human Mesenchymal Stem Cells Induce Long-Term Neurogenic and Anti-Inflammatory Effects and Improve Cognitive But Not Motor Performance in a Rat Model of Parkinson’s Disease,” Regenerative Medicine 10, no. 4 (2015):431–446.

[111] R. M.Heris, M.Shirvaliloo, S.Abbaspour-Aghdam, et al., “The Potential Use of Mesenchymal Stem Cells and Their Exosomes in Parkinson’s Disease Treatment,” Stem Cell Research & Therapy 13 (2022):371.

[112] D.Giunti, B.Parodi, C.Usai, et al., “Mesenchymal Stem Cells Shape Microglia Effector Functions Through the Release of CX3CL1,” Stem Cells 30, no. 9 (2012):2044–2053.

[113] Q.Long, D.Upadhya, B.Hattiangady, et al., “Intranasal MSC-Derived A1-Exosomes Ease Inflammation, and Prevent Abnormal Neurogenesis and Memory Dysfunction After Status Epilepticus,” Proceedings of the National Academy of Sciences 114, no. 17 (2017): E3536.

[114] W.Chen, Y.Huang, J.Han, et al., “Immunomodulatory Effects of Mesenchymal Stromal Cells-Derived Exosome,” Immunologic Research 64, no. 4 (2016):831–840.

[115] T.Togo, O.Katsuse, and E.Iseki, “Nitric Oxide Pathways in Alzheimer’s Disease and Other Neurodegenerative Dementias,” Neurological Research 26, no. 5 (2004):563–566.

[116] S. S.Wang, J.Jia, and Z.Wang, “Mesenchymal Stem Cell-Derived Extracellular Vesicles Suppresses iNOS Expression and Ameliorates Neural Impairment in Alzheimer’s Disease Mice,” Journal of Alzheimer’s Disease 61, no. 3 (2018):1005–1013.

[117] A. M.El-Mahalaway and N. E.-E. El-Azab, “The Potential Neuroprotective Role of Mesenchymal Stem Cell-Derived Exosomes in Cerebellar Cortex Lipopolysaccharide-Induced Neuroinflammation in Rats: a Histological and Immunohistochemical Study,” Ultrastructural Pathology 44, no. 2 (2020):159–173.

[118] X.Cheng, G.Zhang, L.Zhang, et al., “Mesenchymal Stem Cells Deliver Exogenous miR-21 via Exosomes to Inhibit Nucleus Pulposus Cell Apoptosis and Reduce Intervertebral Disc Degeneration,” Journal of Cellular and Molecular Medicine 22, no. 1 (2018):261–276.

[119] M. B.Jiménez-Castro, M. ECornide-Petronio, J. Gracia-Sancho, and C.Peralta, “Inflammasome-Mediated Inflammation in Liver Ischemia-Reperfusion Injury,” Cells 8, no. 10 (2019):1131.

[120] X.Li, J.Liao, X.Su, et al., “Human Urine-Derived Stem Cells Protect Against Renal Ischemia/Reperfusion Injury in a Rat Model via Exosomal miR-146a-5p Which Targets IRAK1,” Theranostics 10, no. 21 (2020):9561–9578.

[121] H. K.Eltzschig and T.Eckle, “Ischemia and Reperfusion—From Mechanism to Translation,” Nature Medicine 17, no. 11 (2011):1391–1401.

[122] Z.Yu, Y.Wen, N.Jiang, et al., “TNF-α Stimulation Enhances the Neuroprotective Effects of Gingival MSCs Derived Exosomes in Retinal Ischemia-Reperfusion Injury via the MEG3/miR-21a-5p Axis,” Biomaterials 284 (2022):121484.

[123] X.Liao, X.Song, J.Li, et al., “An Injectable Co-Assembled Hydrogel Blocks Reactive Oxygen Species and Inflammation Cycle Resisting Myocardial Ischemia-Reperfusion Injury,” Acta Biomaterialia 149 (2022):82–95.

[124] R.Prakash, A.Vyawahare, R.Sakla, et al., “NLRP3 Inflammasome-Targeting Nanomicelles for Preventing Ischemia–Reperfusion-Induced Inflammatory Injury,” ACS Nano 17, no. 9 (2023):8680–8693.

[125] M.Franke, M.Bieber, P.Kraft, A. N. R.Weber, G.Stoll, and M. K.Schuhmann, “The NLRP3 Inflammasome Drives Inflammation in Ischemia/Reperfusion Injury After Transient Middle Cerebral Artery Occlusion in Mice,” Brain, Behavior, and Immunity 92 (2021):221–231.

[126] L.Ye, S.He, X.Mao, Y. Zhang, Y.Cai, and S.Li, “Effect of Hepatic Macrophage Polarization and Apoptosis on Liver Ischemia and Reperfusion Injury During Liver Transplantation,” Frontiers in immunology 11 (2020):1193.

[127] X.Yuan, X.Wang, C.Chen, J. Zhou, and M.Han, “Bone Mesenchymal Stem Cells Ameliorate Ischemia/Reperfusion-Induced Damage in Renal Epithelial Cells via microRNA-223,” Stem Cell Research & Therapy 8 (2017):146.

[128] L.Wang, L.Qing, H.Liu, et al., “Mesenchymal Stromal Cells Ameliorate Oxidative Stress-Induced Islet Endothelium Apoptosis and Functional Impairment via Wnt4-β-Catenin Signaling,” Stem Cell Research & Therapy 8 (2017):188.

[129] H.Xin, Y.Li, B.Buller, et al., “Exosome-Mediated Transfer of miR-133b From Multipotent Mesenchymal Stromal Cells to Neural Cells Contributes to Neurite Outgrowth,” Stem Cells 30, no. 7 (2012):1556–1564.

[130] S.Sahoo and D. W. Losordo, “Exosomes and Cardiac Repair After Myocardial Infarction,” Circulation Research 114, no. 2 (2014):333–344.

[131] H.Xin, Y.Li, Y.Cui, J. J. Yang, Z. G.Zhang, and M.Chopp, “Systemic Administration of Exosomes Released From Mesenchymal Stromal Cells Promote Functional Recovery and Neurovascular Plasticity after Stroke in Rats,” Journal of Cerebral Blood Flow and Metabolism 33, no. 11 (2013):1711–1715.

[132] C.Iadecola and J.Anrather, “The Immunology of Stroke: From Mechanisms to Translation,” Nature Medicine 17, no. 7 (2011):796–808.

[133] G.Heusch, “Myocardial Ischaemia–Reperfusion Injury and Cardioprotection in Perspective,” Nature Reviews Cardiology 17, no. 12 (2020):773–789.

[134] A.Sahu, J.Jeon, M. S.Lee, et al., “Nanozyme Impregnated Mesenchymal Stem Cells for Hepatic Ischemia-Reperfusion Injury Alleviation,” ACS Applied Materials & Interfaces 13, no. 22 (2021):25649–25662.

[135] A. B. BAngulski, L. G. Capriglione, M.Batista, et al., “The Protein Content of Extracellular Vesicles Derived From Expanded Human Umbilical Cord Blood-Derived CD133+ and Human Bone Marrow-Derived Mesenchymal Stem Cells Partially Explains Why Both Sources Are Advantageous for Regenerative Medicine,” Stem Cell Reviews and Reports 13, no. 2 (2017):244–257.

[136] Y.Zhang, Y.Li, Q.Wang, et al., “Attenuation of Hepatic Ischemia-Reperfusion Injury by Adipose Stem Cell-Derived Exosome Treatment via ERK1/2 and GSK-3β Signaling Pathways,” International Journal of Molecular Medicine 49, no. 2 (2021):13.

[137] Z.Sun, J.Wu, Q.Bi, and W.Wang, “Exosomal lncRNA TUG1 Derived From Human Urine-Derived Stem Cells Attenuates Renal Ischemia/Reperfusion Injury by Interacting With SRSF1 to Regulate ASCL4-mediated Ferroptosis,” Stem Cell Research & Therapy 13 (2022):297.

[138] C.Piao, Q.Zhang, J.Xu, et al., “Optimal Intervention Time of ADSCs for Hepatic Ischemia-Reperfusion Combined With Partial Resection Injury in Rats,” Life Sciences 285 (2021):119986.

[139] Q.Pan, X.Kuang, S.Cai, et al., “miR-132-3p Priming Enhances the Effects of Mesenchymal Stromal Cell-Derived Exosomes on Ameliorating Brain Ischemic Injury,” Stem Cell Research & Therapy 11 (2020):260.

[140] T.-C.Lai, T.-L.Lee, Y.-C.Chang, et al., “MicroRNA-221/222 Mediates ADSC-Exosome-Induced Cardioprotection Against Ischemia/Reperfusion by Targeting PUMA and ETS-1,” Frontiers in Cell and Developmental Biology 8 (2020):569150.

[141] L.Zhang, Q.Wei, X.Liu, et al., “Exosomal microRNA-98-5p From Hypoxic Bone Marrow Mesenchymal Stem Cells Inhibits Myocardial Ischemia–Reperfusion Injury by Reducing TLR4 and Activating the PI3K/akt Signaling Pathway,” International Immunopharmacology 101 (2021):107592.

[142] S.Lv, H.Liu, and H.Wang, “The Interplay Between Autophagy and NLRP3 Inflammasome in Ischemia/Reperfusion Injury,” International Journal of Molecular Sciences 22, no. 16 (2021):8773.

[143] F.Wang, Q.Gao, J.Yang, et al., “Artemisinin Suppresses Myocardial Ischemia–Reperfusion Injury via NLRP3 Inflammasome Mechanism,” Molecular and Cellular Biochemistry 474, no. 1–2 (2020):171–180.

[144] J.Zhang, L.Huang, X.Shi, et al., “Metformin Protects Against Myocardial Ischemia-Reperfusion Injury and Cell Pyroptosis via AMPK/NLRP3 Inflammasome Pathway,” Aging 12, no. 23 (2020):24270–24287.

[145] Z.Meng, M.-Y.Song, C.-F.Li, and J. Q. Zhao, “shRNA Interference of NLRP3 Inflammasome Alleviate Ischemia Reperfusion-Induced Myocardial Damage Through Autophagy Activation,” Biochemical and Biophysical Research Communications 494, no. 3 (2017):728–735.

[146] H.Liu, C. M.Lo, O. W. H.Yeung, et al., “NLRP3 Inflammasome Induced Liver Graft Injury Through Activation of Telomere-Independent RAP1/KC Axis,” Journal of Pathology 242, no. 3 (2017):284–296.

[147] A. A.Shigeoka, J. L.Mueller, A.Kambo, et al., “An Inflammasome-Independent Role for Epithelial-Expressed Nlrp3 in Renal Ischemia-Reperfusion Injury,” Journal of Immunology 185, no. 10 (2010):6277–6285.

[148] X.Liu, M.Zhang, H.Liu, et al., “Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Attenuate Cerebral Ischemia-Reperfusion Injury-Induced Neuroinflammation and Pyroptosis by Modulating Microglia M1/M2 Phenotypes,” Experimental Neurology 341 (2021):113700.

[149] L.Gao, F.Qiu, H.Cao, et al., “Therapeutic Delivery of microRNA-125a-5p Oligonucleotides Improves Recovery From Myocardial Ischemia/Reperfusion Injury in Mice and Swine,” Theranostics 13, no. 2 (2023):685–703.

[150] J.Zhao, X.Li, J.Hu, et al., “Mesenchymal Stromal Cell-Derived Exosomes Attenuate Myocardial Ischaemia-Reperfusion Injury Through miR-182-Regulated Macrophage Polarization,” Cardiovascular Research 115, no. 7 (2019):1205–1216.

[151] X.Xie, X.Yang, J.Wu, et al., “Exosome From Indoleamine 2,3-Dioxygenase-overexpressing Bone Marrow Mesenchymal Stem Cells Accelerates Repair Process of Ischemia/Reperfusion-Induced Acute Kidney Injury by Regulating Macrophages Polarization,” Stem Cell Research & Therapy 13 (2022):367.

[152] Y.Zhao, Y.Gan, G.Xu, K.Hua, and D.Liu, “Exosomes From MSCs Overexpressing microRNA-223-3p Attenuate Cerebral Ischemia Through Inhibiting Microglial M1 Polarization Mediated Inflammation,” Life Sciences 260 (2020):118403.

[153] R.Li, K.Zhao, Q.Ruan, et al., “Bone Marrow Mesenchymal Stem Cell-Derived Exosomal microRNA-124-3p Attenuates Neurological Damage in Spinal Cord Ischemia-Reperfusion Injury by Downregulating Ern1 and Promoting M2 Macrophage Polarization,” Arthritis Research & Therapy 22, no. 1 (2020):75.

[154] C.-M.Pu, C.-W.Liu, C.-J.Liang, et al., “Adipose-Derived Stem Cells Protect Skin Flaps Against Ischemia/Reperfusion Injury via IL-6 Expression,” Journal of Investigative Dermatology 137, no. 6 (2017):1353–1362.

[155] Q.Zhang, C.Piao, J.Xu, et al., “ADSCs-Exo Attenuates Hepatic Ischemia–Reperfusion Injury After Hepatectomy by Inhibiting Endoplasmic Reticulum Stress and Inflammation,” Journal of Cellular Physiology 238, no. 3 (2023):659–669.

[156] S. W.Lim, K. W.Kim, B. M.Kim, et al., “Alleviation of Renal Ischemia/Reperfusion Injury by Exosomes From Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells,” Korean Journal of Internal Medicine 37, no. 2 (2022):411–424.

[157] J. S.Pixley, “Mesenchymal Stem Cells to Treat Type 1 Diabetes,” Biochimica et Biophysica Acta (BBA) 1866, no. 4 (2020):165315.

[158] L.Ahmed and K.Al-Massri, “New Approaches for Enhancement of the Efficacy of Mesenchymal Stem Cell-Derived Exosomes in Cardiovascular Diseases,” Tissue Engineering and Regenerative Medicine 19, no. 6 (2022):1129–1146.

[159] S.Keshtkar, M.Kaviani, Z.Jabbarpour, et al., “Protective Effect of Nobiletin on Isolated Human Islets Survival and Function Against Hypoxia and Oxidative Stress-Induced Apoptosis,” Scientific Reports 9 (2019):11701.

[160] D.Wen, Y.Peng, D.Liu, Y. Weizmann, and R. I.Mahato, “Mesenchymal Stem Cell and Derived Exosome as Small RNA Carrier and Immunomodulator to Improve Islet Transplantation,” Journal of Controlled Release 238 (2016):166–175.

[161] M.Bozorgmehr, S.Gurung, S.Darzi, et al., “Endometrial and Menstrual Blood Mesenchymal Stem/Stromal Cells: Biological Properties and Clinical Application,” Frontiers in Cell and Developmental Biology 8 (2020):497.

[162] M.Kouhestani, J.Ai, M.Safari, et al., “Study of Anti-Inflammatory and Immunomodulatory Potential of Endometrial Mesenchymal Stem Cells-Derived Exosomes With Micro-Ultrasound (µUS) Guidance in Regeneration β-Islets on T1D Animal Model,” Journal of Drug Delivery Science and Technology 86 (2023):104666.

[163] E.Xiang, B.Han, Q.Zhang, et al., “Human Umbilical Cord-Derived Mesenchymal Stem Cells Prevent the Progression of Early Diabetic Nephropathy Through Inhibiting Inflammation and Fibrosis,” Stem Cell Research & Therapy 11 (2020):336.

[164] J.Li, H.Xue, T.Li, et al., “Exosomes Derived From Mesenchymal Stem Cells Attenuate the Progression of Atherosclerosis in ApoE–/- Mice via miR-let7 Mediated Infiltration and Polarization of M2 Macrophage,” Biochemical and Biophysical Research Communications 510, no. 4 (2019):565–572.

[165] W.Yang, R.Yin, X.Zhu, et al., “Mesenchymal Stem-Cell-Derived Exosomal miR-145 Inhibits Atherosclerosis by Targeting JAM-A,” Molecular Therapy - Nucleic Acids 23 (2021):119–131.

[166] F.Sani, M.Soufi Zomorrod, N.Azarpira, and M.Soleimani, “The Effect of Mesenchymal Stem Cell-Derived Exosomes and miR17-5p Inhibitor on Multicellular Liver Fibrosis Microtissues,” Stem Cells International 2023 (2023):8836452.

[167] Y.Li, A.Chakraborty, B. R. S.Broughton, et al., “Comparing the Renoprotective Effects of BM-MSCs Versus BM-MSC-Exosomes, When Combined With an Anti-Fibrotic Drug, in Hypertensive Mice,” Biomedicine & Pharmacotherapy 144 (2021):112256.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm – Future Medicine published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).